{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:16:10Z","timestamp":1764173770462,"version":"build-2065373602"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T00:00:00Z","timestamp":1327881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (case series)<\/jats:p>\n                    <jats:p>Level of Evidence\u20034<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Finasteride (Proscar) and dutasteride (Avodart) are 5\u2010\u03b1 reductase inhibitors (5\u2010ARIs) used to treat LUTS in men with benign prostatic enlargement. Because these drugs suppress androgens, the theory has been put forward that 5\u2010ARIs might prevent the development of prostate cancer. Careful analysis of two randomized controlled trials, however, showed that, in the clinical setting, this was not the case, and that these drugs can increase the occurrence of more aggressive high\u2010grade disease. Because of this, the U.S. Food and Drug Administration did not approve 5\u2010ARIs for the primary prevention of prostate cancer and notified healthcare professionals about a change in the \u2018Warnings and Precautions\u2019 for these drugs.<\/jats:p>\n                    <jats:p>Interest remains among some for using 5\u2010ARIs in men diagnosed with very low\u2010risk prostate cancer to delay the progression from clinically indolent disease to clinically significant disease requiring treatment. The present study investigated whether 5\u2010ARI use among men with very low\u2010risk prostate cancer in an active surveillance (AS) programme would reduce the number of cancers reclassified to clinically significant disease on surveillance biopsy. Our results do not support the use of 5\u2010ARIs for slowing or preventing cancer progression in men with low\u2010risk prostate cancer, but do suggest that men with very low\u2010risk prostate cancer who take 5\u2010ARIs for LUTS are unlikely to be at increased risk for the development of high grade disease during AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To determine whether 5\u2010\u03b1 reductase inhibitor (5\u2010ARI) use delays cancer reclassification in an active surveillance (AS) cohort.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>We performed a retrospective study of 587 men enrolled in an AS programme, who had no history of 5\u2010ARI use.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Chi\u2010squared and\n                            <jats:italic>t<\/jats:italic>\n                            \u2010tests were used to compare characteristics of 5\u2010ARI users and non\u2010users.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Univariable and multivariable proportional hazards models, treating 5\u2010ARI use as a time\u2010dependent covariate, were used to evaluate the influence of 5\u2010ARIs on the risk of a subsequent biopsy no longer meeting criteria for continued AS (i.e. reclassification).<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>5\u2010ARI use was initiated in 47 men while on AS.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Men using 5\u2010ARIs had larger prostates and higher PSA levels at diagnosis.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>During 5\u2010ARI use, PSA levels and prostate volume deceased by mean values of 47% and 11%, respectively.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Men using 5\u2010ARIs had a mean of 2.5 surveillance biopsies while on the drug. Reclassification occurred in 17% of 5\u2010ARI users compared with 31% of non\u2010users (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.04).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Multivariable models (adjusting for age, \u03b1\u2010blocker use, PSA level, %free PSA, PSA density, prostate volume and number\/percent biopsy core involvement at diagnosis) showed nonsignificant risk reductions for reclassification in 5\u2010ARI users as determined by either tumour extent (hazard ratio [HR]= 0.37 (95% confidence interval [CI] 0.12 to 1.13),\n                            <jats:italic>P<\/jats:italic>\n                            = 0.08) or grade (HR = 0.8 (95% CI 0.25\u20132.59),\n                            <jats:italic>P<\/jats:italic>\n                            = 0.7).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Treatment with 5\u2010ARIs did not significantly alter the outcome of biopsy reclassification by grade in men with very low\u2010risk prostate cancer.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10875.x","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T13:33:13Z","timestamp":1327930393000},"page":"651-657","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effect of treatment with 5\u2010\u03b1 reductase inhibitors on progression in monitored men with favourable\u2010risk prostate cancer"],"prefix":"10.1111","volume":"110","author":[{"given":"Ashley E.","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip M.","family":"Pierorazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Landis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Ballentine","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Trock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,30]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.12.868"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.135"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.7311"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.12.042"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908127"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030660"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2007.05.006"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.12.018"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8112"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.01.001"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030656"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.01.001"},{"key":"e_1_2_8_14_2","unstructured":"FDA.Oncologic Drugs Advisory Comittee Metting regarding AVODART (dutasteride) NDA 21319\/S0024.2010. Available at:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommitte\/UCM234934. Accessed December 2010"},{"key":"e_1_2_8_15_2","unstructured":"FDA.Oncologic Drugs Advisory Comittee Metting regarding PROSCAR (finasteride) NDA 20180\/S034.2010Available at:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommitte\/UCM234934. Accessed December 2010"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.09.035"},{"key":"e_1_2_8_17_2","article-title":"Dutasteride reduces prostate cancer progression and cancer diagnosis on re\u2010biopsy in the REDEEM active surveillance study","author":"Fleshner N","year":"2011","journal-title":"SUO"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10875.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10875.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:51:13Z","timestamp":1761756673000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10875.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,30]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10875.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10875.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2012,1,30]]},"assertion":[{"value":"2012-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}